<p>Price T Rowe Associates Inc. MD 在第一季度削减了其在 Pacira BioSciences, Inc.（NASDAQ: PCRX - Free Report）的持股比例，根据其最近向证券交易委员会披露的信息，持股比例下降了 17.8%。该机构投资者在本季度出售了 71,733 股股票后，拥有公司股票的 332,020 股。Price T Rowe Associates Inc. MD 在最近季度结束时拥有 Pacira BioSciences 价值 970.3 万美元的股份，占比 0.71%。</p>
<p>获取 <strong>Pacira BioSciences</strong> 警报：</p>
<p>许多其他对冲基金最近也买入并出售了该公司的股票。Vanguard Group Inc.在第一季度将其对 Pacira BioSciences 的持股比例提高了 0.3%。Vanguard Group Inc.现在拥有公司股票 5,113,384 股，价值 1.49413 亿美元，比上一季度增加了 14,960 股。Frontier Capital Management Co. LLC 在第四季度将其对 Pacira BioSciences 的持仓比例提高了 15.8%。Frontier Capital Management Co. LLC 现在拥有公司股票 2,084,542 股，价值 7,033.2 万美元，比上一季度增加了 285,045 股。Dimensional Fund Advisors LP 在第四季度将其对 Pacira BioSciences 的持仓比例提高了 1.3%。Dimensional Fund Advisors LP 现在拥有公司股票 1,411,767 股，价值 4,763.3 万美元，比上一季度增加了 17,949 股。Vestal Point Capital LP 在第四季度购入了 Pacira BioSciences 的新股份，价值约 4,048.8 万美元。最后，Clearbridge Investments LLC 在第一季度将其对 Pacira BioSciences 的持仓比例提高了 2.3%。Clearbridge Investments LLC 现在拥有公司股票 1,172,150 股，价值 3,425 万美元，比上一季度增加了 26,463 股。99.73% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些研究公司最近发布了关于 PCRX 的报告。加拿大皇家银行将 Pacira BioSciences 的目标股价从 42.00 美元降至 37.00 美元，并在周三的研究报告中为该公司设定了 “表现优异” 的评级。雷蒙德詹姆斯将 Pacira BioSciences 的目标股价从 41.00 美元降至 37.00 美元，并在周三的研究报告中为该公司设定了 “表现优异” 的评级。Needham &amp; Company LLC 重申了对 Pacira BioSciences 的 “买入” 评级，并设定了 43.00 美元的目标股价。HC Wainwright 重申了对 Pacira BioSciences 的 “买入” 评级，并在 7 月 2 日星期二的一份报告中设定了 57.00 美元的目标股价。最后，Truist Financial 将 Pacira BioSciences 的目标股价从 45.00 美元降至 30.00 美元，并在 7 月 25 日星期四的一份报告中为该股设定了 “买入” 评级。一位分析师对该股票进行了持有评级，八位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股目前的平均评级为 “买入”，平均目标股价为 41.44 美元。</p>
<p><strong>查看我们关于 Pacira BioSciences 的最新研究报告</strong></p>
<h2>Pacira BioSciences 内部买卖情况</h2>
<p>据悉，Pacira BioSciences 的另一内部消息显示，内部人士 Jonathan Slonin 于 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均价格出售，交易总额为 143,192.84 美元。交易完成后，该内部人士现在持有公司 44,569 股股票，价值 1,273,336.33 美元。该交易已在向 SEC 提交的文件中披露，可在 SEC 网站上查看。另外，首席运营官 Daryl Gaugler 于 6 月 13 日星期四出售了 1,000 股股票。股票以 28.38 美元的平均价格出售，交易总额为 28,380.00 美元。交易完成后，该首席运营官现在直接持有公司 116,040 股股票，价值 3,293,215.20 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接访问。此外，内部人士 Jonathan Slonin 于 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均价格出售，交易总额为 143,192.84 美元。交易完成后，该内部人士现在直接持有公司 44,569 股股票，价值 1,273,336.33 美元。此次交易的披露信息可在此处找到。内部人士在过去 90 天内已出售了总价值 621,118 美元的 22,095 股公司股票。内部人士持有公司股票的比例为 6.40%。</p>
<h2>Pacira BioSciences 股价上涨 2.5%</h2>
<p>PCRX 股票周五开盘价为 21.26 美元。Pacira BioSciences, Inc.的 12 个月最低价为 19.34 美元，最高价为 40.16 美元。该公司的速动比率为 4.78，流动比率为 6.82，负债权益比为 0.67。公司的 50 天移动平均价格为 25.03 美元，200 天移动平均价格为 27.83 美元。该公司的市值为 9.8072 亿美元，市盈率为 14.87，贝塔系数为 0.88。</p>
<p>Pacira BioSciences（NASDAQ: PCRX - Get Free Report）最近公布了截至 5 月 7 日星期二的季度收益结果。公司报告的每股收益为 0.42 美元，低于每股 0.46 美元的共识预期。Pacira BioSciences 的净利润率为 9.21%，净资产收益率为 13.22%。该季度公司的营收为 1.6712 亿美元，而分析师预计为 1.6543 亿美元。股票分析师预测，Pacira BioSciences, Inc.今年将实现 2.13 美元的每股收益。</p>
<h2>Pacira BioSciences 公司简介（免费报告）</h2>
<p>Pacira BioSciences, Inc 从事开发、制造、营销、分销和销售非阿片类疼痛管理和再生健康解决方案给美国的医疗从业者。该公司提供 EXPAREL，一种布比卡因脂质体注射悬液；ZILRETTA，一种曲安奈德缓释注射悬液；以及 iovera 系统，一种非阿片类手持式冷冻镇痛设备，用于向靶神经产生受控的冷温度剂量。</p>
<h2>推荐故事</h2>
<ul>
<li>五支我们比 Pacira BioSciences 更喜欢的股票</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>Hims &amp; Hers 股价下跌，因 DexCom 担忧：分析师预测反弹</li>
<li>投资中降级意味着什么？</li>
<li>Snap 季度营收指引不及预期，股价暴跌</li>
<li>资产配置：成功投资组合的关键。您是否关注您的资产配置？</li>
<li>英特尔在糟糕的财报后市值蒸发四分之一</li>
</ul>
<p><strong>想看看其他对 PCRX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Pacira BioSciences, Inc. (NASDAQ:PCRX - 免费报告) 的最新 13F 申报和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 罗根和卡尔森警告：当心数字货币的威胁（来自 Priority Gold）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3"/></p>
<h2>现在是否值得投资$1,000 在 Pacira BioSciences？</h2>
<p>在考虑 Pacira BioSciences 之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街顶尖和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶尖分析师悄悄告诉客户现在购买的股票...而 Pacira BioSciences 不在名单上。</p>
<p>虽然 Pacira BioSciences 目前在分析师中有 “中等买入” 评级，但顶尖分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

Pacira制药

<p>Price T Rowe Associates Inc. MD 在第一季度减持 Pacira BioSciences 17.8% 的持股比例。其他对冲基金也买入和卖出了该公司的股票。华尔街分析师预测该公司将有增长，平均目标股价为 41.44 美元。内部人士在过去 90 天内共出售了 22,095 股价值 621,118 美元的公司股票</p>

<p>Price T Rowe Associates Inc. MD cut its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 17.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 332,020 shares of the company's stock after selling 71,733 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.71% of Pacira BioSciences worth $9,703,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Price T Rowe Associates Inc. MD 在第一季度削减了其在 Pacira BioSciences, Inc.（NASDAQ: PCRX - Free Report）的持股比例，根据其最近向证券交易委员会披露的信息，持股比例下降了 17.8%。该机构投资者在本季度出售了 71,733 股股票后，拥有公司股票的 332,020 股。Price T Rowe Associates Inc. MD 在最近季度结束时拥有 Pacira BioSciences 价值 970.3 万美元的股份，占比 0.71%。</p>
</div><p>Get <strong>Pacira BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pacira BioSciences</strong> 警报：</p>
</div><p>A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock valued at $149,413,000 after buying an additional 14,960 shares in the last quarter. Frontier Capital Management Co. LLC lifted its position in shares of Pacira BioSciences by 15.8% in the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company's stock worth $70,332,000 after purchasing an additional 285,045 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Pacira BioSciences by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company's stock worth $47,633,000 after purchasing an additional 17,949 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Pacira BioSciences in the fourth quarter worth approximately $40,488,000. Finally, Clearbridge Investments LLC lifted its position in shares of Pacira BioSciences by 2.3% in the first quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company's stock worth $34,250,000 after purchasing an additional 26,463 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>许多其他对冲基金最近也买入并出售了该公司的股票。Vanguard Group Inc.在第一季度将其对 Pacira BioSciences 的持股比例提高了 0.3%。Vanguard Group Inc.现在拥有公司股票 5,113,384 股，价值 1.49413 亿美元，比上一季度增加了 14,960 股。Frontier Capital Management Co. LLC 在第四季度将其对 Pacira BioSciences 的持仓比例提高了 15.8%。Frontier Capital Management Co. LLC 现在拥有公司股票 2,084,542 股，价值 7,033.2 万美元，比上一季度增加了 285,045 股。Dimensional Fund Advisors LP 在第四季度将其对 Pacira BioSciences 的持仓比例提高了 1.3%。Dimensional Fund Advisors LP 现在拥有公司股票 1,411,767 股，价值 4,763.3 万美元，比上一季度增加了 17,949 股。Vestal Point Capital LP 在第四季度购入了 Pacira BioSciences 的新股份，价值约 4,048.8 万美元。最后，Clearbridge Investments LLC 在第一季度将其对 Pacira BioSciences 的持仓比例提高了 2.3%。Clearbridge Investments LLC 现在拥有公司股票 1,172,150 股，价值 3,425 万美元，比上一季度增加了 26,463 股。99.73% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms have recently issued reports on PCRX. Royal Bank of Canada reduced their price target on shares of Pacira BioSciences from $42.00 to $37.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Raymond James reduced their price target on shares of Pacira BioSciences from $41.00 to $37.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $43.00 price target on shares of Pacira BioSciences in a research report on Wednesday. HC Wainwright restated a &#34;buy&#34; rating and issued a $57.00 price objective on shares of Pacira BioSciences in a report on Tuesday, July 2nd. Finally, Truist Financial dropped their price objective on Pacira BioSciences from $45.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, July 25th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $41.44.</p>
<div class="lb-trans"><p>一些研究公司最近发布了关于 PCRX 的报告。加拿大皇家银行将 Pacira BioSciences 的目标股价从 42.00 美元降至 37.00 美元，并在周三的研究报告中为该公司设定了 “表现优异” 的评级。雷蒙德詹姆斯将 Pacira BioSciences 的目标股价从 41.00 美元降至 37.00 美元，并在周三的研究报告中为该公司设定了 “表现优异” 的评级。Needham &amp; Company LLC 重申了对 Pacira BioSciences 的 “买入” 评级，并设定了 43.00 美元的目标股价。HC Wainwright 重申了对 Pacira BioSciences 的 “买入” 评级，并在 7 月 2 日星期二的一份报告中设定了 57.00 美元的目标股价。最后，Truist Financial 将 Pacira BioSciences 的目标股价从 45.00 美元降至 30.00 美元，并在 7 月 25 日星期四的一份报告中为该股设定了 “买入” 评级。一位分析师对该股票进行了持有评级，八位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股目前的平均评级为 “买入”，平均目标股价为 41.44 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Pacira BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Pacira BioSciences 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling at Pacira BioSciences</h2>
<div class="lb-trans"><h2>Pacira BioSciences 内部买卖情况</h2>
</div><p>In other Pacira BioSciences news, insider Jonathan Slonin sold 5,012 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $28.57, for a total transaction of $143,192.84. Following the transaction, the insider now owns 44,569 shares in the company, valued at $1,273,336.33. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, COO Daryl Gaugler sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total value of $28,380.00. Following the completion of the sale, the chief operating officer now directly owns 116,040 shares of the company's stock, valued at $3,293,215.20. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Slonin sold 5,012 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $28.57, for a total value of $143,192.84. Following the completion of the sale, the insider now directly owns 44,569 shares of the company's stock, valued at $1,273,336.33. The disclosure for this sale can be found here. Insiders have sold a total of 22,095 shares of company stock worth $621,118 over the last 90 days. Insiders own 6.40% of the company's stock.</p>
<div class="lb-trans"><p>据悉，Pacira BioSciences 的另一内部消息显示，内部人士 Jonathan Slonin 于 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均价格出售，交易总额为 143,192.84 美元。交易完成后，该内部人士现在持有公司 44,569 股股票，价值 1,273,336.33 美元。该交易已在向 SEC 提交的文件中披露，可在 SEC 网站上查看。另外，首席运营官 Daryl Gaugler 于 6 月 13 日星期四出售了 1,000 股股票。股票以 28.38 美元的平均价格出售，交易总额为 28,380.00 美元。交易完成后，该首席运营官现在直接持有公司 116,040 股股票，价值 3,293,215.20 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接访问。此外，内部人士 Jonathan Slonin 于 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均价格出售，交易总额为 143,192.84 美元。交易完成后，该内部人士现在直接持有公司 44,569 股股票，价值 1,273,336.33 美元。此次交易的披露信息可在此处找到。内部人士在过去 90 天内已出售了总价值 621,118 美元的 22,095 股公司股票。内部人士持有公司股票的比例为 6.40%。</p>
</div><h2>Pacira BioSciences Trading Up 2.5 %</h2>
<div class="lb-trans"><h2>Pacira BioSciences 股价上涨 2.5%</h2>
</div><p>Shares of PCRX stock opened at $21.26 on Friday. Pacira BioSciences, Inc. has a 12 month low of $19.34 and a 12 month high of $40.16. The company has a quick ratio of 4.78, a current ratio of 6.82 and a debt-to-equity ratio of 0.67. The business's 50 day moving average is $25.03 and its two-hundred day moving average is $27.83. The company has a market cap of $980.72 million, a PE ratio of 14.87 and a beta of 0.88.</p>
<div class="lb-trans"><p>PCRX 股票周五开盘价为 21.26 美元。Pacira BioSciences, Inc.的 12 个月最低价为 19.34 美元，最高价为 40.16 美元。该公司的速动比率为 4.78，流动比率为 6.82，负债权益比为 0.67。公司的 50 天移动平均价格为 25.03 美元，200 天移动平均价格为 27.83 美元。该公司的市值为 9.8072 亿美元，市盈率为 14.87，贝塔系数为 0.88。</p>
</div><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The company had revenue of $167.12 million for the quarter, compared to analyst estimates of $165.43 million. Equities analysts predict that Pacira BioSciences, Inc. will post 2.13 EPS for the current year.</p>
<div class="lb-trans"><p>Pacira BioSciences（NASDAQ: PCRX - Get Free Report）最近公布了截至 5 月 7 日星期二的季度收益结果。公司报告的每股收益为 0.42 美元，低于每股 0.46 美元的共识预期。Pacira BioSciences 的净利润率为 9.21%，净资产收益率为 13.22%。该季度公司的营收为 1.6712 亿美元，而分析师预计为 1.6543 亿美元。股票分析师预测，Pacira BioSciences, Inc.今年将实现 2.13 美元的每股收益。</p>
</div><h2>Pacira BioSciences Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Pacira BioSciences 公司简介（免费报告）</h2>
</div><p>Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.</p>
<div class="lb-trans"><p>Pacira BioSciences, Inc 从事开发、制造、营销、分销和销售非阿片类疼痛管理和再生健康解决方案给美国的医疗从业者。该公司提供 EXPAREL，一种布比卡因脂质体注射悬液；ZILRETTA，一种曲安奈德缓释注射悬液；以及 iovera 系统，一种非阿片类手持式冷冻镇痛设备，用于向靶神经产生受控的冷温度剂量。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Pacira BioSciences</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Hims &amp; Hers Stock Falls on DexCom Fears: Analysts Predict Rally</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Snap's Stock Plummets on Q2 Revenue Guidance Shortfall</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Intel Loses a Quarter of Its Value After Horrible Earnings Report</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>五支我们比 Pacira BioSciences 更喜欢的股票</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>Hims &amp; Hers 股价下跌，因 DexCom 担忧：分析师预测反弹</li>
<li>投资中降级意味着什么？</li>
<li>Snap 季度营收指引不及预期，股价暴跌</li>
<li>资产配置：成功投资组合的关键。您是否关注您的资产配置？</li>
<li>英特尔在糟糕的财报后市值蒸发四分之一</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PCRX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 PCRX 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Pacira BioSciences, Inc. (NASDAQ:PCRX - 免费报告) 的最新 13F 申报和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Rogan and Carlson Warning: Beware the Digital Currency Menace (From Priority Gold)(Ad)</p>
<div class="lb-trans"><p>→ 罗根和卡尔森警告：当心数字货币的威胁（来自 Priority Gold）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8947&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Pacira BioSciences right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Pacira BioSciences？</h2>
</div><p>Before you consider Pacira BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Pacira BioSciences 之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶尖和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶尖分析师悄悄告诉客户现在购买的股票...而 Pacira BioSciences 不在名单上。</p>
</div><p>While Pacira BioSciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pacira BioSciences 目前在分析师中有 “中等买入” 评级，但顶尖分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Pacira BioSciences, Inc.（纳斯达克代码：PCRX）的持仓被 Price T Rowe Associates Inc. MD 减少